Practical considerations in CAR-T therapy
Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, discusses the practical considerations that need to be taken into account when implementing chimeric antigen receptor (CAR) T-cell therapy. With an increasing amount of CAR T-cell products available to treat lymphoma, it is essential to select the patients that will benefit the most from this immunotherapy. Prof. Nagler explains that several factors are used to predict the response to CAR T-cell therapy, including organ function, tumor volume, LDH and platelet levels, p53 mutation status and extranodal disease. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.
Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, discusses the practical considerations that need to be taken into account when implementing chimeric antigen receptor (CAR) T-cell therapy. With an increasing amount of CAR T-cell products available to treat lymphoma, it is essential to select the patients that will benefit the most from this immunotherapy. Prof. Nagler explains that several factors are used to predict the response to CAR T-cell therapy, including organ function, tumor volume, LDH and platelet levels, p53 mutation status and extranodal disease. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.